[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0415304A - métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou variante bioativos, e de uma composição imunogênica - Google Patents

métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou variante bioativos, e de uma composição imunogênica

Info

Publication number
BRPI0415304A
BRPI0415304A BRPI0415304-9A BRPI0415304A BRPI0415304A BR PI0415304 A BRPI0415304 A BR PI0415304A BR PI0415304 A BRPI0415304 A BR PI0415304A BR PI0415304 A BRPI0415304 A BR PI0415304A
Authority
BR
Brazil
Prior art keywords
antigen
cancer
patient
increasing
methods
Prior art date
Application number
BRPI0415304-9A
Other languages
English (en)
Inventor
Claudine Elviere Marie Bruck
Catherine Marie Ghislai Gerard
Zdenka Ludmila Jonak
Original Assignee
Glaxosmithkline Biolog Sa
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Smithkline Beecham Corp filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0415304A publication Critical patent/BRPI0415304A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MéTODOS DE AUMENTAR UMA RESPOSTA IMUNE A UM ANTìGENO EM UM MAMìFERO, E DE REDUZIR A SEVERIDADE DE UM CáNCER EM UM PACIENTE, PREPARAçãO COMBINADA, KIT FARMACêUTICO, E, USOS DE UM POLIPEPTìDEO DE IL- 18 OU SEU FRAGMENTO OU VARIANTE BIOATIVOS, E DE UMA COMPOSIçãO IMUNOGêNICA". A invenção diz respeito a uma terapia de combinação que encontra utilidade no tratamento ou profilaxia de doenças infecciosas, canceres, doenças autoimunes e condições relacionadas.
BRPI0415304-9A 2003-10-13 2004-10-11 métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou variante bioativos, e de uma composição imunogênica BRPI0415304A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0323965.4A GB0323965D0 (en) 2003-10-13 2003-10-13 Immunogenic compositions
PCT/EP2004/011620 WO2005039634A1 (en) 2003-10-13 2004-10-11 Vaccine compositions comprising an interleukin 18 and saponin adjuvant system

Publications (1)

Publication Number Publication Date
BRPI0415304A true BRPI0415304A (pt) 2006-12-05

Family

ID=29559205

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415304-9A BRPI0415304A (pt) 2003-10-13 2004-10-11 métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou variante bioativos, e de uma composição imunogênica

Country Status (17)

Country Link
US (1) US20070212329A1 (pt)
EP (1) EP1687025A1 (pt)
JP (1) JP2007508272A (pt)
KR (1) KR20070054136A (pt)
CN (1) CN1889977A (pt)
AU (1) AU2004283457A1 (pt)
BR (1) BRPI0415304A (pt)
CA (1) CA2541695A1 (pt)
CO (1) CO5700790A2 (pt)
GB (1) GB0323965D0 (pt)
IL (1) IL174544A0 (pt)
IS (1) IS8374A (pt)
MA (1) MA28149A1 (pt)
NO (1) NO20061912L (pt)
RU (1) RU2006111847A (pt)
WO (1) WO2005039634A1 (pt)
ZA (1) ZA200602950B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236807A1 (en) * 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7524824B2 (en) * 2003-09-04 2009-04-28 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7727561B2 (en) 2001-08-31 2010-06-01 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
CN100471486C (zh) * 2002-08-12 2009-03-25 戴纳伐克斯技术股份有限公司 免疫调节组合物,其制备方法和使用方法
US8614197B2 (en) * 2003-10-09 2013-12-24 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
CA2541425C (en) * 2003-10-09 2013-01-29 Pacific Arrow Limited Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7488753B2 (en) * 2003-10-09 2009-02-10 Pacific Arrow Limited Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof
US7514412B2 (en) * 2003-10-09 2009-04-07 Pacific Arrow Limited Anticancer biangeloyl saponins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
DE102004022200B4 (de) 2004-05-05 2006-07-20 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
US9382285B2 (en) 2004-09-07 2016-07-05 Pacific Arrow Limited Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells
US8735558B2 (en) * 2005-02-14 2014-05-27 Pacific Arrow Limited Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
US8586719B2 (en) * 2005-04-27 2013-11-19 Pacific Arrow Limited Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
DE102006008023B4 (de) 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets
EP2796575B8 (en) 2006-09-08 2020-04-01 Actinium Pharmaceuticals, Inc. Method for the purification of radium from different sources
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
CN106310293A (zh) * 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
WO2009089535A2 (en) 2008-01-11 2009-07-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptide vaccine and vaccination strategy against mycobacterium
US20110070298A1 (en) 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
KR101333852B1 (ko) * 2008-06-27 2013-11-27 조에티스 엘엘씨 신규한 면역증강 조성물
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
PL2444103T3 (pl) * 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
US9499577B2 (en) 2009-07-16 2016-11-22 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
US20120277308A1 (en) 2010-07-16 2012-11-01 Pacific Arrow Limited compounds for treating cancer and other diseases
US9434677B2 (en) 2009-07-16 2016-09-06 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
PL2528621T3 (pl) * 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
EP2575878B1 (en) * 2010-05-28 2018-06-13 Zoetis Belgium S.A. Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
RU2482866C2 (ru) * 2010-10-07 2013-05-27 Общество с ограниченной ответственностью "Аллоферон" Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина-18
SG11201401177WA (en) 2011-10-06 2014-04-28 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
GB201205361D0 (en) * 2012-03-27 2012-05-09 Univ Nottingham Trent Breast cancer assay
ES2843509T3 (es) * 2013-01-04 2021-07-19 Obi Pharma Inc Vacunas con mayor densidad de antígeno carbohidratado y nuevo adyuvante de saponina
KR20230145241A (ko) * 2014-10-01 2023-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
GB201522329D0 (en) * 2015-12-17 2016-02-03 Glaxosmithkline Biolog S A And Inst Nat De La Sante Et De La Rech Medicale Inserm And Université Pie Use of adjuvants for the prevention and/or treatment of autoimmune diseases
JP6963019B2 (ja) 2016-10-31 2021-11-05 アイジーン インコーポレイテッドEyegene Inc. 免疫調節剤及び陽イオン性リポソームを含む免疫増強用組成物及びその用途
CN107952069A (zh) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 重组疫苗及其应用
EP3669890A1 (en) * 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
TR201907085A2 (tr) 2019-05-10 2020-11-23 Univ Yeditepe Parazi̇tleri̇n ve parazi̇tlerden elde edi̇len ekstraselüler vezi̇külleri̇n kanser tedavi̇si̇nde kullanimi
US20230073321A1 (en) * 2019-12-13 2023-03-09 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical composition and use thereof
WO2022034555A1 (en) * 2020-08-13 2022-02-17 Janssen Biopharma, Inc. Polynucleotide constructs and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2143716T3 (es) * 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6355256B1 (en) * 1994-09-30 2002-03-12 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
JP2002513547A (ja) * 1998-05-07 2002-05-14 アクゾ・ノベル・エヌ・ベー ワクチン・アジュバントとしてのインターロイキン−１８の使用
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
WO2001057219A2 (en) * 2000-02-02 2001-08-09 Schering Corporation Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
AU2001236807A1 (en) * 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using

Also Published As

Publication number Publication date
CO5700790A2 (es) 2006-11-30
EP1687025A1 (en) 2006-08-09
MA28149A1 (fr) 2006-09-01
RU2006111847A (ru) 2007-11-20
JP2007508272A (ja) 2007-04-05
IS8374A (is) 2006-03-27
IL174544A0 (en) 2006-08-01
CA2541695A1 (en) 2005-05-06
NO20061912L (no) 2006-06-02
GB0323965D0 (en) 2003-11-19
WO2005039634A1 (en) 2005-05-06
AU2004283457A1 (en) 2005-05-06
KR20070054136A (ko) 2007-05-28
CN1889977A (zh) 2007-01-03
US20070212329A1 (en) 2007-09-13
ZA200602950B (en) 2007-09-26

Similar Documents

Publication Publication Date Title
BRPI0415304A (pt) métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou variante bioativos, e de uma composição imunogênica
BRPI0415315A (pt) métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou derivado bioativos, e de uma composição imunogênica
BRPI0607326B8 (pt) composição de vacina, uso da referida composição e kit em partes
BRPI0610093A2 (pt) composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
CR9994A (es) Vacuna terapéutica
IL228069A0 (en) Antibodies specific to fcyriib and methods of using them
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
ME00425B (me) Liječenje sa anti-vegf antitijelima
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CY1109454T1 (el) Θεραπεια για τη νοσο του αλτσχαϊμερ και της αγγειακης εγκεφαλικης αμυλοειδοπαθειας
MX2008013993A (es) Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
BRPI0415249A (pt) terapia de combinação para infecção por hcv
ES2362589B1 (es) Exosomas derivados de reticulocitos infectados con plasmodium sp., método para su obtención y su uso.
BR112021013415A2 (pt) Proteínas de fusão multifuncionais e usos das mesmas
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
ATE398463T1 (de) Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
BRPI0508365A (pt) composições imunogênicas para chlamydia pneumoniae
MX2023000376A (es) Fármacos de enlazador de antifolato, y conjugados de anticuerpo-fármaco.
MX2022012165A (es) Interaccion de proteinas de sars-cov-2 con mecanismos moleculares y celulares de celulas huespedes y formulaciones para tratar covid-19.
UY27827A1 (es) Composiciones y su uso terapeutico
EA201171352A1 (ru) Антигенсвязывающие фрагменты антитела и их применение для лечения или диагностики глазных болезней

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]